EGON-ZEHNDER
16.9.2021 07:02:08 CEST | Business Wire | Press release
Egon Zehnder, the world’s preeminent leadership advisory firm, today announced the results of a study which surveyed 972 CEOs worldwide, capturing the pulse on how CEO roles and expectations are evolving at the hand of momentous global challenges and emerging trends. The study uncovered that self-reflection and personal development have jumped to be among the top of CEO priorities as they become increasingly self-aware, realizing that the key to prosperity is to improve the human side of their leadership.
As heightened demands for workplace equality and new pressures around hybrid work continue to dramatically shape business culture, CEOs worldwide are reevaluating their role, how they engage with their team, as well as how they hold their organization – and themselves – accountable for making their businesses future-ready. Today, CEOs view prioritizing their own development and tapping into the intrinsic sources of energy of the people in their organizations as crucial to navigating through complex business environments.
Key findings include:
- 90% of CEOs report they have moved to the center of increasingly louder, more diverse and diverging voices. When asked about the impact of recent circumstances on their organization, most CEOs highlighted accelerated decision making and change, and greater economic uncertainty. These shifts speak to the complexities and rapid evolution that is reshaping business – and that CEOs will answer to more stakeholders and be measured in new and emerging ways.
- 83% of leaders find it essential to reflect on their own leadership style – up from 66% in the 2018 study, The CEO: A Personal Reflection . CEOs are expanding their ability to be adaptive, relational, and self-aware. They are committed to listening to diverse perspectives and are increasingly seeking feedback from new places – including team members, chairs, mentors, consultants, and other CEOs. In addition, female CEOs are more likely to gather feedback from a wide range of sources – and are more likely than male counterparts to seek guidance from fellow CEOs, mentors and family members.
- 78% of CEOs strongly agree that they need to continue their self-transformation – three times as much from 2018. CEOs also agree strongly on the importance of the “dual journey,” a path where leaders believe viewing their personal development and their organization’s growth as an interrelated journey will affect optimal change. Our most striking finding is the near-unanimous agreement among a thousand leaders that, “As CEO, I need the capacity to transform myself as well as my organization.”
- Two-thirds of CEOs report that the ultimate metrics that steer their decisions have remained consistent, despite new social and economic business expectations that they express support for. Given this conflict, it’s not clear whether CEOs have a direct path to deliver on their ambitions with traditional financial metrics as the dominant decision driver for most CEOs.
- An analysis of open-ended answers has shown that nearly 500 CEOs, more than half of all respondents, see relational capabilities as a key blind spot. Specifically, less than half of CEOs (44%) report they feel fully aligned with their teams, and even fewer with their boards – pointing to heightened levels of tension and increased need for collaboration.
“CEOs recognize that today’s unprecedented business complexities require a significant shift in leadership – and that change must begin by looking inward with new levels of self-reflection and personal development. This isn’t self-indulgent naval gazing; it’s what our teams, organizations and stakeholders expect of our CEOs,” said Jill Ader, Global Chairwoman of Egon Zehnder. “Now, more than ever, traditional business acumen must be equally balanced with empathy and compassion in order to gain their teams’ and organizations’ emotional commitment, navigate business complexities and build productive, inspiring workplaces.”
Navigating through these complex environments demand CEOs increase their personal capacity to be adaptive, relational and self-aware, stressed Kati Najipoor-Schuette and Dick Patton, who co-lead Egon Zehnder’s CEO advisory group and co-authored this study. Especially today, these capacities need to be increasingly balanced with traditional leadership strengths, strategic planning and a relentless performance orientation. Mastering these skills requires leaders to increase their capacity to listen, trust in a broader network of stakeholders and communicate more authentically than ever before.
As a result of honing these skills and taking a more human-centric approach to leadership, CEOs will evolve the resiliency, leadership and adaptability of themselves – and their organizations.
For more information on Egon Zehnder’s CEO Study, which surveyed 972 CEOs worldwide, visit www.egonzehnder.com/it-starts-with-the-CEO .
About Egon Zehnder
Egon Zehnder is the world’s preeminent leadership advisory firm, inspiring leaders to navigate complex questions with human answers. With more than 55 years of experience advising clients on chief executive leadership, we know that the selection of a CEO is the midpoint of a process, not the end. That’s why we partner with our clients to deliver a comprehensive and effective CEO transition, succession, development and onboarding support. We help organizations get to the heart of their leadership challenges and offer honest feedback and insights to help leaders realize their true being and purpose. Our 525 consultants across 63 offices and 37 countries are former industry and functional leaders who collaborate seamlessly across geographies, industries and functions to deliver the full power of the Firm to every client, every time. We believe that together we can transform people, organizations and the world through leadership.
For more information, visit www.egonzehnder.com and follow us on LinkedIn and Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005058/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
